NR3C2 and Hyperkalemia: Finerenone has certain advantages over traditional corticosteroid receptor blockers, such as lower occurrence of hyperkalemia than spironolactone (Ba et al., 2015; Filippatos et al., 2016; Pitt et al., 2013; Rico-Mesa et al., 2020), high affinity for MR, and more promising as a corticosteroid receptor blocker (Amazit et al., 2015).